Tamiflu shortens the duration of influenza symptoms by only half a day, does not stop person-to-person spread and increases the risk of nausea say the authors of a new review who want Governments to rethink stockpiling neuraminidase inhibitors.
Quality and IP issues are driving firms back to the US and Europe for their contract manufacturing according to experts, but Kemwell says there are still opportunities for Indian CMOs.
AmerisourceBergen (ABC) plans to buy a minority stake in a Brazilian drug wholesaler and outlined plans for a $100m distribution services joint-venture in the rapidly expanding market.
The Board of Directors at Indian firm Orchid has approved the sale of its API business to Hospira, bringing the acquisition a step closer to completion.
Aesica has predicted that CMO sector consolidation will continue and hinted that it is considering strategic acquisitions as a part of a bid to generate $1bn revenue.
Nearly a quarter of drugs made in Jammu & Kashmir and 10% of those produced in Himachal Pradesh are substandard according to new testing data published by CDSCO.
WuXi PharmaTech has revealed that demand for its manufacturing services increased significantly last year and forecast that its "open access" approach will help it sustain growth into 2014.
Publication of a US FDA enforcement report detailing a recall by Ranbaxy in January saw the beleaguered Indian drugmakers’ share price fall 3% last week.
In a sign of further consolidation, CRO INC Research has acquired CRO MEK Consulting and will absorb its more than 40 employees based in the Middle East and north Africa.
Scientists developing vaccines for potentially deadly diseases like influenza, SARS and HIV struggle to find a CRO with the right capabilities according to contractor TNO Triskelion.
CRO Pharmaceutical Product Development (PPD) and the Charité – Universitätsmedizin hospital in Berlin are collaborating to increase the volume of clinical trials conducted in Germany.
The National Institutes of Health and 10 pharmaceutical companies have launched a partnership to transform the current model for identifying and validating promising biological targets for Type 2 diabetes, Alzheimer’s disease, lupus and rheumatoid arthritis.
Pfizer says its ‘off the shelf’ aseptic processing capacity is shifting the paradigm of pharma manufacturing, with emerging markets and personalised medicine driving the change.
Novartis has confirmed that pharma jobs will be reallocated in 2014 in a continuation of the productivity drive that saved the firm $2.8bn (EUR2bn) last year.
Increased in-house API production and manufacturing in India will lower the costs of Hospira’s injectables, the firm says, as it looks past current remediation efforts.
CEO Tom Pike emphasised Quintiles’ credentials as a Big Pharma collaborator and highlighted personalised medicines as a key driver for the CRO at an investment conference last week.
European dependence on drugs and APIs made outside the EU is still ‘alarming’ despite recently introduced anti-falsified meds laws according to the European Fine Chemicals Group (EFCG).
AMRI says it intends to expand its fill/finish capability and progress its business into higher value technology following the recent all clear at its once troubled Burlington facility.
The US FDA is positioned to increase drug plant inspections in China after US President Barack Obama signed a $1.1tr (€881bn) budget for fiscal 2014 into law on Saturday.
Complex generics will represent over 50% of Teva’s generic market by 2017, the firm says, but investments in delivery technology will have positive implications across the full business.
GMP auditors need a professional qualification similar to QP status according to a group whose new training scheme is designed to create a competency benchmark.
AMEC has announced its plan to buy US firm Foster Wheeler AG for $3.2bn (€2.3bn) in a deal that includes the latter’s pharmaceutical plant design services business.
CMO Recipharm has set out to sell a new own-brand infectious disease medication it developed in partnership with fellow Sweden-based firm Astimex Pharma.
Contract sales and marketing people who want to work for GSK should think about adopting the new target-free remuneration policy the UK pharmaceutical firm outlined earlier this week.
The increasingly crowded Chinese preclinical model market gained a new entrant last month with US preclinical CRO Crown Bioscience partnering with Shanghai academics to set up a research centre.
A lawsuit alleging that the US FDA unlawfully detained a batch of acetaminophen API destined for CMO Gemini Pharmaceuticals could have significant impact on the drug industry's definition of an ‘end user.'
Soon to merge CMO Patheon has increased solid dosage form production capacity at its site in the UK and posted an improved set of preliminary results for the financial year.
As part of its global streamlining strategy a second Irish Merck & Co plant has been earmarked to close but the firm says it remains committed to Ireland.
Actavis says it is restructuring a Californian manufacturing facility at a cost of 56 jobs weeks after the announced closure of a plant in North Carolina.
Unilife has signed a $40m long-term supply agreement with Hikma and says it is committed to becoming the world’s largest and most successful injectable drug delivery systems supplier.
Pfizer says it intends to shutter a manufacturing facility in Puerto Rico just days after Merck & Co. announced it was reducing its footprint on the island.
